Pharmacodynamics of julibroside J₈ and J₁₂ in inhibiting angiogenesis

Background: Ablizia julibrissin could inhibit the proliferation of cancer cells in vitro and in vivo. However, the effects of the compositions Julibroside J₈ and J₁₂ on the angiogenesis are still poorly understood.

Objective: We compared the pharmacodynamics of julibroside J₈ and J₁₂ in inhibiting angiogenesis in vitro and in vivo.

Methods: Julibroside J₈ and J₁₂ were separated from the crude extract of Ablizia julibrissin. The effects of julibroside J₈ and julibroside J₁₂ on growth, migration, and matrigel tube formation of human microvascular endothelial cells (HMEC-1) were explored. In addition, the in vivo anti-angiogenic effect of julibroside J₈ and J₁₂ was evaluated on a chorioallantoic membrane (CAM).

Results: HMEC-1 cells showed dose-dependent inhibition of growth, migration, and tube formation, when treated with 0.5-4 μg/ml julibroside J₈ or 0.1-0.5 μg/ml julibroside J₁₂ respectively. The formation of microvessels on CAM was also inhibited by julibroside J₈ or julibroside J₁₂ at concentrations of 10-100 μg.egg^-1 or 5-50 μg.egg^-1 respectively.

Conclusion: Julibroside J₁₂ confers more potent inhibitory effect on angiogenesis than julibroside J₈ does.